90558-39-7

Usage

InChI:InChI=1/C9H10N2O6S/c12-9(13)5-6-10-18(16,17)8-4-2-1-3-7(8)11(14)15/h1-4,10H,5-6H2,(H,12,13)

Upstream product

• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 107-95-9 3-amino propanoic acid 
• 3196-73-4 methyl 3-aminopropanoate hydrochloride 

Downstream Products

• 666844-25-3 4-Methyl-1-[3-(2-nitrobenzenesulfonylamino)propionyl]-piperazine 
• 909786-44-3 (S)-N¹-((S)-1,5-diamino-1-imino-6,15-dioxo-2,7,12,16-tetraazahenicosan-21-yl)-2-(2-(2,4-dihydroxyphenyl)acetamido)-succinamide tris(2,2,2-trifluoroacetate) 
• 718615-12-4 [[2-(2-tert-butoxycarbonylamino-ethylcarbamoyl)-ethyl]-(2-nitro-benzenesulfonyl)-amino]-acetic acid ethyl ester 
• 718615-13-5 [[2-(2-tert-butoxycarbonylamino-ethylcarbamoyl)-ethyl]-(2-nitro-benzenesulfonyl)-amino]-acetic acid 
• 934421-22-4 N-(cyclohexylcarbamoyl-phenyl-methyl)-N-(2-hydroxy-ethyl)-3-(2-nitro-benzenesulfonylamino)-propionamide 
• 718615-11-3 {2-[3-(2-nitro-benzenesulfonylamino)-propionylamino]-ethyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Preparation of N-Substituted N-Arylsulfonylglycines and Their Use in Peptoid Synthesis

To increase the chemical diversity accessible with peptoids and peptide-peptoid hybrids, N-alkylated arylsulfonamides were used to prepare side chain protected N-substituted glycines compatible with solid-phase synthesis. The described procedures give acc

PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents -RB, -CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.,; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

TRAM linker: A safety-catch linker for the traceless release of acrylamides

Equation presented. A novel safety-catch linker for the solid-phase synthesis of small-molecule libraries containing electrophilic reactive groups has been developed. Upon cleavage from solid support, the linker generates a Michael acceptor (an acrylamide